Study found inhibiting IL6 could also reduce activity of NF-κB pathway, lower production of inflammatory mediators and mitigate the pro-inflammatory state within tumor microenvironment (Zhu et al., 2022). This evidence concerns the gene NFKB1 and neoplasm.